FDA posts manufacturing warning to Lonza
Zurich – The FDA has posted a manufacturing warning to Lonza following an inspection of the firm's microbial production site for Eisai’s cancer drug Ontak in Hopkinton. However, analysts at Vontobel said that the impact of the warning for Lonza’s revenues is not significant. Eisai’s revenue with the treatment for patients with cutanous T cell lymphoma would be in the range of US$ 70m, while Lonza is making US$5-7m per year. They maintained their rating for Lonza at "hold" with a share target value at CHF 48.